Plain-English translation of NCT06649474 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is studying how a protein called HMGB1 in your blood might explain why some patients experience liver and nerve damage from oxaliplatin chemotherapy. Researchers will measure this protein in patients with resectable (surgically removable) stomach, esophageal, or pancreatic cancer who receive oxaliplatin-based chemotherapy before surgery. If they find a clear link, doctors could one day predict and prevent these side effects in future patients.
About half of patients receiving oxaliplatin develop a liver complication called sinusoidal obstruction syndrome, which can worsen surgery outcomes and increase cancer recurrence. Researchers believe a specific protein triggers this problem, but this link has never been studied directly in patients—understanding it could lead to better ways to protect your liver while still effectively treating your cancer.
You likely qualify if…
You likely don't qualify if…
You would have blood samples collected at multiple timepoints during your regular cancer treatment—before chemotherapy, during treatment, after treatment, and possibly during follow-up visits. The study involves no additional procedures beyond standard care; researchers simply measure a specific protein in your blood to track how it changes and whether it relates to side effects you may experience. Your participation helps doctors understand why these complications occur so they can develop better prevention strategies for future patients.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
France